Radiopharm Theranostics RADX
NASDAQ RADX
$0.88 -0.07 (-7.70%)
At close: Nov 9, 2026 · 4:00 PM EST

Radiopharm Theranostics (RADX) Accumulated Expenses (2024)

Updated

Radiopharm Theranostics (RADX) recorded Accumulated Expenses of $1.76 million in fiscal Q4 2025 (quarter ended Jun 30, 2025), up 59.1% from $1.11 million a year earlier.

Analysis

Radiopharm Theranostics (RADX) Accumulated Expenses (2024) Analysis & Trends

  • Across earlier fiscal years, Accumulated Expenses came in at $1.11 million in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,261.99 Bn 1,235.61 Bn 20.46 Bn
2 Johnson & Johnson 678.93 Bn 598.79 Bn 17.30 Bn
3 AbbVie 518.29 Bn 486.30 Bn 13.12 Bn
4 Merck 365.98 Bn 328.92 Bn 13.19 Bn
5 Novartis Ag 316.85 Bn 290.09 Bn -
6 Astrazeneca 293.40 Bn 267.29 Bn 13.26 Bn
7 Amgen 251.78 Bn 203.43 Bn 7.58 Bn
8 Gilead Sciences 210.61 Bn 185.71 Bn 6.73 Bn
9 Pfizer 166.87 Bn 114.23 Bn 12.56 Bn
10 Radiopharm Theranostics 2.70 Bn 2.62 Bn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 4.18 Mn
API Access

Radiopharm Theranostics Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=RADX&period=max&api_key=YOUR_API_KEY